When your patients have unresolved depressive symptoms after 6 weeks of treatment with an antidepressant, consider adding SEROQUEL XR® (quetiapine fumarate) Extended-Release Tablets.
*“Patients” means all covered lives (Medicare MA, Medicare PDP, Medicare SN) at Tiers 1-3 in the US calculated by Fingertip Formulary, as of September 2011, that do not require additional information to the health plan in order for SEROQUEL XR to be covered.
†May be subject to quantity limitations.
AstraZeneca does not endorse any individual Commercial, Medicare Part D, or Medicaid Plan or Plans.
1. Prescribing Information for SEROQUEL XR. AstraZeneca Pharmaceuticals LP, Wilmington, DE.
2. Fingertip Formulary, September 2011.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1‑800‑FDA‑1088.